Tony Mok, MD, discusses the next steps for pembrolizumab (Keytruda) as a treatment option for patients with non-small cell lung cancer after the phase III KEYNOTE-042 trial.
Tony Mok, MD
Articles by Tony Mok, MD
Latest Updated Articles
Dr. Mok Discusses Next Steps With Pembrolizumab in NSCLCPublished: May 9th 2019 | Updated: